Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Antonio Llombart‐Cussac; José Manuel Pérez-García; Manuel Ruíz Borrego; Pablo Tolosa; Salvador Blanch; Adela Fernández-Ortega; Ander Urruticoechea; Isabel Blancas; Cristina Saura; Beatriz Rojas; Begoña Bermejo; José Ponce; María Gión; Patricia Cortez-Castedo; Elisenda Llabrés; Elena Gálve; Juan Cueva; Ana López; José Luis Alonso-Romero; Santiago González-Santiago; Eduardo Martínez de Dueñas; Eva Ciruelos; Griselda Martrat; Petra Gener; Daniel Alcalá-López; Miguel Sampayo-Cordero; Fernando Gómez‐Peralta; Javier Cortés

doi:10.1016/j.eclinm.2024.102520

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Llombart‐Cussac et al. (2024) studied this question.

synapsesocial.com/papers/68e6f83cb6db6435876721fe https://doi.org/10.1016/j.eclinm.2024.102520

View Full Paper

Ask AI

Bookmark

Share

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Ask about this paper

Abstract

Discussion

Cite This Study

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading